Transformational cell therapies for patients with pancreatic disease

VIEW OUR SUPPLEMENTARY PROSPECTUS

OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.

VIEW OUR VIDEO TO LEARN ABOUT KOLIGO’S DEDICATION TO THE DEVELOPMENT OF TRANSFORMATIVE CELL THERAPIES.

Koligo Therapeutics, Inc. is a regenerative medicine company dedicated to the commercialization and development of transformative cell therapies for pancreatic diseases. View our video below to learn about Kyslecel™ and our pipeline of other product candidates through the use of 3D bioprinting and other manufacturing advances.


Finance News Network, Sydney, Australia
Koligo Therapeutics Limited (ASX:KOL) CEO, Matthew Lehman and Chairman, Peter James talk about the company’s therapies, IPO and strategy, and the incidence of chronic pancreatitis.